Angiogenic factors in chronic lymphocytic leukemia

Xia, Yi; Lu, Ruinan; Li, Jianyong

doi:10.1016/j.leukres.2012.05.021

Cited by 22 publications

(19 citation statements)

References 88 publications

(142 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14][15][16] The aberrant ANGPT2 expression found both in cancers and leukemias, together with the evidence that ANGPT2 inhibitors are able to reduce tumor angiogenesis in vivo, strongly suggest a pivotal role of ANGPT2 in this process. [17][18][19][20][21][22] Considering the significance of ANGPT2 in influencing CLL behavior, in particular by acting on angiogenesis, the study of molecular mechanisms responsible for its aberrant and variable expression in CLL could be useful to better elucidate the disease pathogenesis and to identify more efficacious therapies. Many studies on ANGPT2 regulation have been performed on normal endothelial cells but limited data exist on tumor cells.…”

Section: Introductionmentioning

confidence: 99%

ANGPT2promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

ANGPT2promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia

et al. 2013

View full text Add to dashboard Cite

show abstract

“…A significant correlation between circulating endothelial cells (CECs) and vWF has been reported [19,20]. These studies, together with the rest of the studies, indicate a possible role for vWF in the angiogenesis process in patients with CLL [21,22]. It has been well known that the nuclear transcription factor [nuclear factor-kappa B (NF-kB)] controls the angiogenic states of vascular endothelial cells and has been reported to be constitutively up-regulated in unstimulated CLL cells.…”

Section: Introductionmentioning

confidence: 84%

Induction of endothelial cell proliferation and von Willebrand factor expression and secretion by leukemic plasma of patients with chronic lymphocytic leukemia before and after inhibition of NF-κB

Shahidi

Razavi²,

Hayat³

2016

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Although certain evidence has indicated a role for angiogenesis in the pathophysiology of hematopoietic malignancies, its role in chronic lymphocytic leukemia (CLL) prognosis is yet to be defined. To our knowledge, the effects of CLL plasma on cell culture have not been addressed. Therefore, we investigated the effects of CLL plasma on cell cycle regulation and von Willebrand factor (vWF) secretion, and expression in human umbilical vein endothelial cell cultures (HUVECs). Since nuclear factor-kappa B (NF-κB) transcription factor has been a therapeutic target for treatment of cancer, we inhibited NF-κB using small interfering RNA to clarify if there is a role for this factor in probable effects. The cells were treated with the plasma of patients with CLL. Subsequently, cell cycle phase distribution, vWF secretion, expression, and storage were detected using ELISA, flow cytometry, and immunohistochemical staining. In addition, NF-κB was inhibited using small interfering RNA. Plasma treatment promoted cell cycle progression by decreasing the cell number in G1 phase, while increasing the cell number in S phase and G2M phase. A significant increase of vWF expression, secretion, and storage was found, associated with the vWF levels of patients' plasma. We found that induction of cell cycle promotion, but not vWF expression and secretion, was partially suppressed by this inhibition. We found that endothelial cell cycle and vWF expression and secretion affected by CLL plasma and NF-κB play a role in the former. These findings would be useful for understanding the prognostic importance of plasma angiogenic factor levels in CLL.

show abstract

“…No drug resistance or toxic side effects have been observed after its use. The level of endostatin has been correlated with the progression and prognosis of a variety of malignant tumors Xia et al, 2012;Moiseev et al, 2013). Fibroblast growth factor 19 (FGF-19) belongs to the FGF family, and is often expressed in the terminal ileum, brain, skin, and other sites.…”

Section: Introductionmentioning

confidence: 99%

Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients

Su¹,

Wang²,

Zhou³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The present study aimed to explore the changes in serum endostatin and fibroblast growth factor 19 (FGF-19) in acute myeloid leukemia patients, and to determine their effects on chemotherapeutic sensitivity. Sixty acute myeloid leukemia patients and 30 healthy controls were included in the study. Patient serum endostatin and FGF-19 levels were measured on admission, and then, standard chemotherapy was administered. The patients were divided into 2 groups according to chemotherapeutic effects: 21 patients in the chemotherapeutic sensitivity group (complete remission + partial remission) and 39 in the chemotherapeutic resistance group (no remission + degradation). A receiver operating characteristic (ROC) curve was used to analyze the relationship of serum endostatin and FGF-19 levels with chemotherapeutic sensitivity in acute myeloid leukemia patients. The levels of serum endostatin and FGF-19 in acute myeloid leukemia patients before chemotherapy were significantly higher than those in the control group. Moreover, these levels significantly decreased after chemotherapy (P < 0.01). The levels of serum endostatin and FGF-19 in the chemotherapeutic sensitivity group were lower than those in the chemotherapeutic resistance group, both before and after chemotherapy (P < 0.05 and P < 0.01, respectively). ROC curve analysis showed that the predictive values of endostatin and FGF-19 were good, and there was no significant difference between these results. In conclusion, serum endostatin and FGF-19 can be used as predictors of chemotherapeutic sensitivity for acute myeloid leukemia patients, and may be important for determining prognosis.

show abstract

Angiogenic factors in chronic lymphocytic leukemia

Cited by 22 publications

References 88 publications

ANGPT2promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia

ANGPT2promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia

Induction of endothelial cell proliferation and von Willebrand factor expression and secretion by leukemic plasma of patients with chronic lymphocytic leukemia before and after inhibition of NF-κB

Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients

Contact Info

Product

Resources

About